Revenues from Contracts and Significant Customers |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2025 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Revenues from Contracts and Significant Customers | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Revenues from Contracts and Significant Customers |
19. Revenues from Contracts and Significant Customers Disaggregation of Total Revenues All of Journey’s product revenues are recorded in the U.S. The Company’s collaboration revenue for the year ended December 31, 2024 is from Cyprium’s agreement with Sentynl (see Note 3). The Company’s revenue - related party for the year ended December 31, 2024 was from Checkpoint’s collaborations with TGTX. The table below summarizes the Company’s revenue for the years ended December 31, 2025 and 2024:
Other revenue for the year ended December 31, 2025, consists of $0.6 million recognized by Journey related to the Cutia Agreement (see Note 7) and $1.4 million recognized by Avenue related to the AnnJi license termination and program transfer (see Note 7). Other revenue for the year ended December 31, 2024, reflects a $1.0 million milestone payment from Cutia triggered by the marketing approval Cutia received in the fourth quarter of 2024 for topical 4% minocycline foam in China (see Note 7). Significant Customers For the years ended December 31, 2025 and 2024, none of Journey’s Dermatology Products customers individually accounted for more than 10.0% of its total gross product revenue. For the year ended December 31, 2025, none of Journey’s Dermatology Products customers accounted for more than 10% of its total accounts receivable balance. For the year ended December 31, 2024, one of Journey’s Dermatology Products customers accounted for more than 10% of its total accounts receivable balance at 10.3%. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|